Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Potential methods to prevent interstitial fibrosis in renal disease
Autore:
Strutz, F;
Indirizzi:
Univ Gottingen, Dept Nephrol & Rheumatol, D-37075 Gottingen, Germany Univ Gottingen Gottingen Germany D-37075 tol, D-37075 Gottingen, Germany
Titolo Testata:
EXPERT OPINION ON INVESTIGATIONAL DRUGS
fascicolo: 11, volume: 10, anno: 2001,
pagine: 1989 - 2001
SICI:
1354-3784(200111)10:11<1989:PMTPIF>2.0.ZU;2-6
Fonte:
ISI
Lingua:
ENG
Soggetto:
GROWTH-FACTOR-BETA; LOW-PROTEIN-DIET; INTERLEUKIN-1 RECEPTOR ANTAGONIST; CONVERTING ENZYME-INHIBITION; INDUCED LUNG FIBROSIS; INTERCELLULAR-ADHESION MOLECULE-1; PRIMARY BILIARY-CIRRHOSIS; BLEOMYCIN-HAMSTER MODEL; ANGIOTENSIN-II BLOCKADE; MATRIX GENE-EXPRESSION;
Keywords:
EGF; FGF-2; fibrosis; progression; pirfenidone; relaxin; TGF-beta 1;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
153
Recensione:
Indirizzi per estratti:
Indirizzo: Strutz, F Univ Gottingen, Dept Nephrol & Rheumatol, Robert Koch Str 40, D-37075 Gottingen, Germany Univ Gottingen Robert Koch Str 40 Gottingen Germany D-37075 any
Citazione:
F. Strutz, "Potential methods to prevent interstitial fibrosis in renal disease", EXPERT OP I, 10(11), 2001, pp. 1989-2001

Abstract

Almost all forms of end stage renal disease (ESRD) are characterised by progressive interstitital fibrosis and tubular atrophy. Since most forms of chronic renal failure are initiated by inflammatory processes, anti-inflammatory strategies can be successful, if initiated early, in preventing progression of the disease process. Unfortunately, in most cases the disease is only detected clinically following robust progression of interstitial fibrosis. In these patients, control of secondary risk factors, such as hypertension and hyperglycaemia, can slow the progression rate but cannot stop the process completely. Certainly, ACE inhibitors remain the mainstay of preserving renal function. However, additional therapies are needed for the effective treatment of progressive renal fibrosis. A number of compounds have shown some very potent antifibrotic properties in vitro and in vivo, and are currently undergoing further evaluation. This review discusses the most promising among them. However, few of the therapeutic agents discussed here have been tested clinically. Studies evaluating the potential of a number of these have just commenced whereas for many others clinical use is still manyyears away. However, some very promising reagents may enhance our clinicalarsenal within a relatively short period of time.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 03/04/20 alle ore 20:36:24